Already have an account? Log in
SEQUORA Retatrutide 40mg is an investigational research compound that activates GLP-1, GIP and glucagon receptors. Available in vial and prefilled pen formats, we offer a choice of formats to help with appetite regulation, glucose metabolism and energy balance.
The 40mg figure indicates the total stated Retatrutide content, not the concentration or amount delivered per withdrawal. Please visit the bottom of this page for dosage guidance and advice.
All of our products are third party laboratory tested to ensure both purity and verification of the peptide itself.
Retatrutide is an investigational compound that activates GIP, GLP-1 and glucagon receptors. Researchers are studying how these three pathways influence appetite, blood sugar regulation and energy metabolism.
Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Retatrutide also activates the glucagon receptor. This additional pathway is being investigated, but it does not automatically make retatrutide safer or more effective.
No. Retatrutide remains investigational and is not an approved weight-loss medicine. Its safety and effectiveness are being evaluated in clinical trials. Retatrutide sold by SEQUORA Peptides, although third party verified and tested is bought and used at your own risk.
Reported side effects include nausea, vomiting, diarrhoea and constipation. Trials have also observed increases in heart rate. Its longer-term safety is still being studied and trial findings cannot establish the safety of separately supplied research products.
Product information, handling and safety
What Temperature should I store my Retatrutide at?
What are the best practices for using Retatrutide safely?
The documentation behind Retatrutide and it's uses
Upon delivery store in a refridgerator between 2-8°C.
Avoid dropping or heavy-handling of your Tirzepatide.
Please do not freeze your SEQUORA Retatrutide Pen as this can compromise the Retatrutide.
Your product has been shipped in secure packaging to prevent any potential issues however if you believe your peptides have been compromised contact us directly.
Your SEQUORA Retatrutide Pen will last 12 months from the date of manufacture providing you follow the storage instructions provided.
SEQUORA Retatrutide Vials before reconstitution can last up to 4 years at -5°C
Retatrutide can be kept at room temperature however it’s shelf life when held at this temperature reduces to 1-2 months.
Before handling your Retatrutide, needles or injection material, ensure your research area is clean and clear.
Wash your hands with warm water and soap and allow to dry fully before handling any SEQUORA products to prevent cross contamination or infection risks.
If at any point the cleanliness of your injection or environment is compromised, restart this step.
Never re-use or share needles/syringes. Ensure your needle tips or syringe is sealed and new before injection.
Before using your SEQUORA Retatrutide Pen, using an alcohol swab, wipe the tip of the cartridge after removing the lid to the pen.
If at any point you touch something unhygienic or potentially dirty, re-wash your hands and use new equipment.
Ensure that your needle tips, syringes and vials are safely disposed of post-use.
This could mean a sharps bin or safe container. Most needle tips and syringes have removable tops that can be replaced onto the used needle.
Try to keep your injection site clean for atleast 30 minutes post-injection to prevent infection risks.
Tirzepatide can cause side effects, although not everyone experiences them. This summary does not cover every possible reaction.
Commonly reported side effects
Other important risks
Potential serious effects include inflammation of the pancreas, gallbladder problems and severe allergic reactions. Low blood sugar is more likely when tirzepatide is combined with insulin or certain other diabetes medicines.
When to seek medical help
Stop use and seek urgent medical attention for severe, persistent stomach pain, which may spread to the back, with or without vomiting.
Call 999 immediately for difficulty breathing or sudden swelling of the lips, tongue or throat.
Speak to a healthcare professional if side effects persist, worsen or concern you.
About this information
This summary is based on safety information for licensed tirzepatide medicines. It does not establish the safety, quality or suitability of this product for human use and is not a substitute for medical advice.
Some mild side effects may improve with changes to eating and drinking habits. These measures cannot prevent serious reactions or make an unlicensed product safe.
Nausea and heartburn
Constipation
Diarrhoea or vomiting
When to get advice
Contact a healthcare professional if symptoms persist or worsen. Seek prompt medical advice if you cannot keep fluids down, pass less urine or feel lightheaded. Discuss troublesome side effects with your prescriber before any planned dose increase.
Symptoms requiring urgent help
Stop use and seek urgent medical attention for severe, persistent stomach pain, particularly if it spreads to the back. Call 999 for difficulty breathing or sudden swelling of the lips, tongue or throat. Do not try to manage these symptoms with dietary changes.
About this information
This advice relates to prescribed tirzepatide treatment. It does not establish the safety, quality or suitability of a SEQUORA product for human use and does not replace individual medical advice.
Retatrutide is studied to be administered once weekly. The schedule below summarises typical dosing information from clinical trials and peer research.
Pen strength: 40 mg in a final volume of 2.4 ml. Calculated dial settings assume delivery of 0.01 ml per dial unit. Check pen strength before every administration.
| Dose | Frequency | 20 mg pen dial setting | Stage and duration |
|---|---|---|---|
| 0.5 mg | Once weekly | 3 | Weeks 1 – 4: Starting dose for the first 4 weeks. |
| 1 mg | Once weekly | 6 | Weeks 5 – 8: Monitor effectiveness and side effects closely, only increase if needed. |
| 2 mg | Once weekly | 12 | Weeks 9 – 12: Monitor effectiveness and side effects closely, only increase if needed. |
| 3 mg | Once weekly | 18 | Weeks 13+: Monitor effectiveness and side effects closely, only increase if needed. |
| 4 mg | Once weekly | 24 | Weeks 13+: Monitor effectiveness and side effects closely, only increase if needed. |
| 5 mg | Once weekly | 30 | Weeks 13+: Monitor effectiveness and side effects closely, only increase if needed. |
We do not recommend exceeding 5 mg / week regardless of clinical trial data, however, if through your own research you have decided to do that, use the below reference sheet to calculate your own dosing.
Dose increases are not automatic
As retatrutide is still in clinical trials, dosing is individually dependant and not fixed. The goal should be to stay on the lowest dose possible while still maintaining the benefits and effects of retatrutide. If you notice hunger returning and your feeling of fullness leaving before your next injection, you can incrementally increase your dose.
Understanding the figures
Doses are expressed in milligrams per weekly administration. Each numbered dial of the pen delivers 0.01ml of liquid or 1 Unit. The SEQUORA 40mg Retatrutide Pen contains 2.4ml of reconstituted Retatrutide meaning every 1 dial = Approximately 0.1667 mg of Retatrutide.
Device limits and verification
The maximum dial setting is 60. This table does not provide instructions for combining injections, if you feel you need more precise control over dosage amounts down to the 0.25mg you should purchase the 20mg Retatrutide Pen instead.
Pen conversion reference: 40 mg in 2.4 ml
Calculated for a device delivering 0.01 ml per dial unit. This is a conversion reference, not a recommended dosing schedule.
| Amount | Pen dial setting | Amount | Pen dial setting |
|---|---|---|---|
| 0.50 mg | 3 | 5.50 mg | 33 |
| 1.00 mg | 6 | 6.00 mg | 36 |
| 1.50 mg | 9 | 6.50 mg | 39 |
| 2.00 mg | 12 | 7.00 mg | 42 |
| 2.50 mg | 15 | 7.50 mg | 45 |
| 3.00 mg | 18 | 8.00 mg | 48 |
| 3.50 mg | 21 | 8.50 mg | 51 |
| 4.00 mg | 24 | 9.00 mg | 54 |
| 4.50 mg | 27 | 9.50 mg | 57 |
| 5.00 mg | 30 | 10.00 mg | 60 |
Check before using this reference
These figures apply only to a 40 mg SEQUORA Retatrutide Pen with a final total volume of 2.4 ml, confirmed to deliver 0.01 ml per dial unit. They do not apply to other concentrations or device calibrations.
The figures describe calculated delivery, not independently measured output. They do not establish a safe dose, suitable frequency or suitability for injection.